An interventional study of ECHO program for DMMC and Usual care in Diabetes Mellitus and Chronic Disease, sponsored by University of New Mexico. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of New Mexico · Not applicable, Interventional, and Treatment
Diabetes mellitus is a chronic condition that affects the body's ability to process sugar effectively, which over time can increase the risk of heart disease, high blood pressure, and kidney damage. Other chronic conditions include high cholesterol, obesity, and depression. Persons with diabetes mellitus and multiple chronic conditions (DMMC) face higher risks of losing physical or mental function, experiencing other chronic conditions, and death. Most of the residents of New Mexico (NM) belong to groups at risk for developing DMMC. Finding quality healthcare is a key factor, as NM also ranks among the largest, poorest, and most rural states. Primary care providers (PCPs) most often treat DMMC patients, but healthcare teams can lack confidence in managing these complex patients and struggle to keep up with recommended guidelines.
This Project ECHO model (ECHO) for DMMC, a telehealth intervention for healthcare teams, can lead to lower blood sugar levels in DMMC patients being treated at NM primary care clinics. ECHO is a "telementoring" program that trains healthcare teams to provide specialized medical care at their local clinics. This is done by connecting healthcare teams with specialist mentors at academic medical centers through videoconferencing sessions. During ECHO program sessions, groups of healthcare teams hear lectures on key topics in DMMC care from experts, and then give presentations of anonymous patient cases by a healthcare teams for discussion and to receive recommendations.
This clinical pragmatic trial aims to learn if the intervention will improve patient blood sugar levels in persons with DMMC who are being treated at selected health clinic sites throughout New Mexico.
The study aims to answer:
Researchers will compare health data for patients empaneled to healthcare teams in the study and the usual care comparator group both before and after the intervention period to see whether the ECHO model has a positive influence on test results.
Persons with diabetes mellitus and multiple (2+) chronic conditions (DMMC) are at increased risk of functional decline, lower quality of life, and mortality. In a state ranked among the largest, poorest, and most rural, a high proportion of the diverse residents of New Mexico (NM) belong to groups at risk for developing DMMC. Lack of access to quality healthcare is a key risk factor. Healthcare teams at Federally Qualified Health Centers (FQHCs) in medically underserved areas must have knowledge of, and be able to implement, evidence-based management guidelines to address disease complexity such as DMMC, but the healthcare teams face barriers including lack of confidence in managing complex DM and comorbid conditions and keeping up with evolving best practice guidelines. Our primary research question is whether the Project ECHO model (ECHO), a telehealth intervention for healthcare teams, can achieve significant and durable reductions in HbA1c levels relative to usual care in patients with DMMC seeking care at NM's FQHCs clinics.
Project ECHO is a "telementoring" program for remotely training healthcare teams to enable the healthcare teams to provide specialized medical care at local clinics under the ongoing mentorship of an interdisciplinary team of specialists based at academic medical centers. The ECHO model uses a combination of didactic and case-based learning to help healthcare teams, specialists, and other participants co-develop treatment plans for their patients with complex conditions. Through iterative guided practice, healthcare teams gain expertise in administering specialized medical care in primary care settings. Unlike traditional direct service or specialty consultation telehealth models, the ECHO model works on the principle of workforce multiplication, expanding access to best practice specialty healthcare by increasing healthcare team capacity to care for DMMC patients closer to their homes.
The ECHO for Diabetes and Multiple Chronic Conditions (E4DMMC) study is a cluster-randomized pragmatic trial, and will investigate the effectiveness of Project ECHO's telementoring intervention, compared to usual care practices, for optimizing the management of DMMC within vulnerable populations seeking treatment in NM FQHC clinics. E4DMMC aims to achieve, relative to the usual care arm: (1) a clinically significant ( ≥0.5%) reduction in HbA1c on average, and ≥15% reduction in rate of patients with HbA1c > 8.5% at 18-months into-intervention; (2) significant and clinically meaningful improvements on secondary clinical outcomes for other chronic conditions (blood pressure, cholesterol level, depressive symptoms, and referrals to smoking cessation); (3) similar improvements in clinical outcomes across telehealth modalities (e.g., audio-only vs. videoconference); (4) increased adoption of clinical best practices; and (5) increased patient activation and satisfaction with care. Thus, we will evaluate outcomes at both healthcare team level and at the level of patient empaneled to the healthcare team.
Our primary patient population consists of an estimated 7000 patients with DMMC actively receiving routine care from the 20 Presbyterian Medical Services (PMS) FQHC clinics with the highest patient volume and identified through PMS EHR. This population is diverse and underserved: 45% are Hispanic/Latino, and 14% are American Indian and Alaska Native; and 48% are insured through Medicaid. Across the 20 clinics, 25-48% of these patients with DM reported an HbA1c > 8.5%. Eleven clinics are in rural or mixed rural/urban counties, serving 55% of all patients with DMMC in this population. The median number of healthcare team members across these clinics is five, including clinicians, registered nurses, physician associates, and medical assistants.
The investigators will partner with PMS, the largest system of FQHC clinics in New Mexico to randomize 20 PMS FQHC clinics, 10 each to the ECHO intervention arm and Usual Care comparator arm. For the intervention, an ECHO program consisting of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, chronic kidney disease (CKD), hypertension, hyperlipidemia, and depression). The comparator will consist of clinical sites where healthcare teams are practicing usual care for DMMC patients, continuing standard practices for ensuring best practice care. Primary outcome data will be tracked for 21 months post-intervention in the ECHO intervention arm.
8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.
This study's planned enrollment of 20 is below the median of 80 across 6,023 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →University of New Mexico is the lead sponsor of 313 studies on the registry; 29 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 23 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
10 FQHCs from the PMS health system will be randomized to the ECHO Intervention Arm. All healthcare team members in the intervention arm will attend ECHO program sessions, and the FQHCs are the primary subjects of the ECHO intervention. However, the investigators examine outcomes at both the level of the healthcare team and at the level of the patients who are empaneled to the healthcare team. Persons with DMMC cared for by the healthcare teams at the FQHC clinics are the patient population for this intervention.
Behavioral: ECHO program for DMMC
10 FQHCs from the PMS health system will be randomized to the comparator arm which is usual care. Persons with DMMC cared for by the healthcare teams at the FQHC clinics are the patient population for this comparator arm.
Behavioral: Usual care
For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.
The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.
HbA1c trajectory
A decreasing trajectory in patients' HbA1c over time during and following ECHO intervention, reaching an average of 0.5% drop 18 months into intervention compared with comparator
Time frame: At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.
HbA1c level in control
15% decreases in per-patient rate of HbA1c\>8.5% by 18 months into intervention, respectively, compared with comparator
Time frame: At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.
Use of any tele-med modalities for patient visits
Percentage of DMMC patients with at least 2 HbA1c tests per year as adherence to recommended DM management across modalities (audio-only vs. videoconference)
Time frame: Every encounter per EHR during 12 months baseline prior to intervention, during the study period (18 months intervention and up to 18 months follow-up for the intervention arm)
Hypertension
Patient blood pressure not in control (systolic blood pressure (SBP)\>130 and/or diastolic blood pressure (DBP)\>80)
Time frame: Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up
Cholesterol
Patient low-density lipoprotein LDL-C
Time frame: Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR
Kidney function
Estimated glomerular filtration rate (eGFR) and/or urine albumin-creatinine ratio (UACR)
Time frame: Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR
Depressive symptoms - Large version
Rate of at least one positive Patient Health Questionnaire (PHQ) -2 per patient per 12-month period. The score ranges from a minimum of 0 and maximum of 6, with a higher score indicating more severe symptoms of major depressive disorder.
Time frame: Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up
Depressive symptoms - Small version
Depression screening score trajectory on PHQ-2 (amongst the total population and amongst those with positive PHQ-2) or PHQ-9 (only amongst those with positive PHQ-2) per 12-month period. PHQ-9 score ranges between a minimum of 0 and a maximum of 27, with the higher the score meaning a greater severity of depression.
Time frame: Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up
Obesity
Body mass index
Time frame: Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up
Receipt of appropriate exams
1. Eye exams 2. Foot exams
Time frame: Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR
Rates of prescribing DM meds in accordance with guidelines
DM meds: metformin, sulfonylureas (glipizide, glimepiride, glyburide), glucagon-like peptide-1 receptor agonist (GLP-1RA) (patients with atherosclerotic cardiovascular disease (ASCVD)), sodium-glucose transport protein 2 inhibitors (SGLT2i) (patients with ASCVD, CKD, heart failure), thiazolidinediones (pioglitazone), GLP-1/GIP RA (tirzepatide), and insulin.
Time frame: Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up
Rates of prescribing hypertension meds in accordance with guidelines
Hypertension meds: thiazide or thiazide like diuretics, angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACE-I), or dihydropyridine calcium channel blockers (CCB).
Time frame: Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up
Rates of prescribing CKD meds in accordance with guidelines
CKD meds: ACE-I or ARB, SGLT2i, or finerenone.
Time frame: Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up
Rates of prescribing hyperlipidemia meds in accordance with guidelines
Hyperlipidemia meds: moderate-intensity statin, OR high-intensity statin.
Time frame: Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up
Rates of prescribing hypertriglyceridemia med in accordance with guidelines
Hypertriglyceridemia meds: icosapent ethyl.
Time frame: Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up
Depression care - Large and Small version
Patient Health Questionnaire (PHQ) -2/PHQ-9 screening completion: PHQ-2 completion rate per primary care encounter over a 12-month period. PHQ-9 completion rate per instance of positive PHQ-2 over a 12-month period. (See Depressive Symptoms for range)
Time frame: Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up
Depression care intervention
Minimally adequate treatment for depression: Depressive disorder diagnosis rate per patient per 12-month period. Amongst patients with a depressive disorder diagnosis, percentage receiving: two or more months of an appropriate antidepressant medication plus four or more visits to any type of prescribing provider per 12-month period, OR 8 or more psychotherapy visits with any professional lasting an average of 30 minutes per 12-month period.
Time frame: Per EHR, -12 to 0 months, 1 to 12 months, 13-24 months
Lifestyle counseling according to guidelines
1. Smoking cessation counseling 2. Diet counseling 3. Physical exercise counseling
Time frame: Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR
Presbyterian Medical Services (PMS) Patient satisfaction survey
PMS conducts routine patient satisfaction survey post each encounter. Survey is proprietary. Improvement in patient satisfaction in ECHO intervention compared with comparator. Score goes from lowest to high (scale of 1 to 5), and increase is better outcome.
Time frame: Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up
Health behaviors
Patient reports: (1) checking blood glucose during the last 7 days; (2) checking their feet during the last 7 days.
Time frame: Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up
Tobacco use
Patient reports smoking cigarettes in the last 30 days.
Time frame: Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up
Diet
Patient reports: (1) soda consumption in last 30 days; (2) high fat foods consumed during last 7 days; (3) spacing carbo- hydrates evenly during last 7 days
Time frame: Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up
Physical exercise
Patient reports physical activity of at least 30 mins during the last 7 days.
Time frame: Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up
HbA1c levels
HbA1c change over intervention and follow-up for DM patients with 1 or no other chronic condition
Time frame: At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.
HbA1c levels and disease progression - pre-DM
HbA1c change over intervention and follow-up for pre-DM patients
Time frame: Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up
HbA1c levels and disease progression - newly diagnosed DM
HbA1c change over intervention and follow-up for newly diagnosed DM or DMMC patients who did not have baseline data
Time frame: At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention.
Patient Activation Measure (PAM)
Short form 13-item Patient Activation Measure. The scale is proprietary, and there is no low or high.
Time frame: Per PMS standard patient survey; during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up
Plan to share: Yes — We will follow PCORI's Policy for Data Management and Data Sharing.
Supporting information: Study protocol, Statistical analysis plan
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.